NCT03531684View on ClinicalTrials.gov

Efficacy and Safety of MMFS in Early AD

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 20, 2018

Primary Completion Date

April 22, 2020

Study Completion Date

April 22, 2020

Conditions
Alzheimer Disease
Interventions
DIETARY_SUPPLEMENT

MMFS-205-SR

Twice daily, oral, 500 mg tablets

DIETARY_SUPPLEMENT

Placebo

Twice daily, oral

Trial Locations (1)

43210

The Ohio State University Wexner Medical Center, Columbus

Sponsors

Lead Sponsor

Neurocentria, Inc.
All Listed Sponsors
collaborator

Ohio State University

OTHER

lead

Neurocentria, Inc.

INDUSTRY

NCT03531684 - Efficacy and Safety of MMFS in Early AD | Biotech Hunter | Biotech Hunter